| (210) | Number of the EPO application | 18786587 |
| (220) | Filing date of the EPO application | 2018.09.26 |
| (80) | EPO patent specification publication (B) | EPB nr. 12/2025, 2025.03.19 |
| (110) | EPO patent number | 3687562 |
| (21) | Number of the application | e 2020 0805 |
| (71) | Name(s) of applicant(s), code of the country | REGENERON PHARMACEUTICALS, INC., US; |
| (72) | Name(s) of inventor(s), code of the country | TESSARI Eben, US;
PAOLINI John, US; |
| (73) | Name(s) of owner(s), code of the country | REGENERON PHARMACEUTICALS, INC., US; |
| (54) | Title of the invention | TREATMENT OF RECURRENT IDIOPATHIC PERICARDITIS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 38/17 (2006.01.01); A61K 39/395 (2006.01.01); A61K 47/68 (2017.01.01); A61P 9/00 (2006.01.01); A61P 29/00 (2006.01.01); A61K 38/20 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2020.08.31 |
| (30) | Priority | 201762563387 P, 2017.09.26, US; 201862616819 P, 2018.01.12, US; 201862625075 P, 2018.02.01, US; 201862639425 P, 2018.03.06, US; 201862654291 P, 2018.04.06, US; 201862691552 P, 2018.06.28, US; 201862716331 P, 2018.08.08, US |
| (86) | International application | PCT/US2018/052985, 2018.09.26 |
| (87) | International publication | WO 2019/067639, 2019.04.04 |